The study revealed that T-DXd anti-tumor activity increased when HER2 expression was high; modest anti-tumor activity was also observed in patients with HER2 IHC 0 and suggested that very low levels of HER2 could allow an uptake of T-DXd and/or partially mediated drug efficacy. This evidence concerns the gene ERBB2 and neoplasm.